Mounjaro (Tirzepatide) Injection 7.5 mg/0.5 mL Prefilled Syringes are a type of medication used to treat type 2 diabetes. They contain the active ingredient tirzepatide, which belongs to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists. This medication is delivered as a pre-filled syringe that contains 7.5 mg of tirzepatide in a solution of 0.5 mL. It is given as a subcutaneous injection (under the skin) once a week and works by mimicking the function of a naturally occurring hormone in the body called GLP-1, which helps regulate blood sugar levels. Mounjaro is intended to be used in conjunction with a healthy diet and exercise to help control blood sugar in adults with type 2 diabetes. It may also help in weight management for people with obesity or overweight. As with any medication, it is important to follow the instructions of a healthcare professional and to report any side effects experienced
Beyond weight loss, 73.5% of participants achieved hemoglobin A1c levels at or below 6.5%, compared to just 15.9% in the placebo group
These products can cause digestive distress and potentially worsen nutrient deficiencies
Safety data for the metforminonly population from SUSTAIN FORTE were also not available and, therefore, no formal adjusted indirect comparisons were conducted
Understanding how to reconstitute tirzepatide , knowing refrigeration requirements , and following correct storage duration guidelines protect the integrity of the compound
The authors do not propose a biochemical mechanism by which semaglutide and NAION might be connected, nor do they know for sure that the patients included in the study who were prescribed semaglutide actually took the medication
